Press Releases

Date Title
1/8/21 Sarepta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
1/7/21 Sarepta Therapeutics Announces Top-line Results for Part 1 of Study 102 Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
12/31/20 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/14/20 Sarepta Therapeutics Announces Executive Management Changes
12/7/20 Sarepta Therapeutics Announces Positive Clinical Results from MOMENTUM, a Phase 2 Clinical Trial of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
12/4/20 Sarepta Therapeutics to Share Clinical Update for SRP-5051, its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy
11/30/20 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/25/20 Sarepta Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference
11/20/20 Sarepta Therapeutics Named One of The Boston Globe’s Top Places to Work 2020
11/5/20 Sarepta Therapeutics Announces Third Quarter 2020 Financial Results and Recent Corporate Developments
Displaying 41 - 50 of 699